Table 1.
Performance Evaluation Panel Characteristics
| Sample Size |
DAT Titer, Cases (%) |
Average Age of Patients (y) |
HIV Statusa (%) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | HEC | Non-VL Disease Condition Controls | Low (≤100) | Medium (1:200–1:6400) | High (>1:6400) | Case | Controls | Unknown | Known |
||
| Positive | Negative | ||||||||||
| East Africa | 250 | 210 | 40 | 0.4 | 8.8 | 90.8 | 14 | 20 | 47.2 | 0 | 52.8 |
| Brazil | 237–250 | 206–209 | 42–45 | 0.0 | 11.6 | 88.4 | 19 | 27 | 98.6 | 0 | 1.4 |
| ISC | 250 | 210 | 39 | 0.0 | 3.2 | 96.8 | 24 | 31 | 50.8 | 0.5 | 48.7 |
Abbreviations: DAT, direct agglutination test; HEC, healthy endemic control; HIV, human immunodeficiency virus; ISC, Indian subcontinent; VL, visceral leishmaniasis.
a Includes cases and controls combined.